Syndax Pharmaceuticals (NASDAQ:SNDX) CMO Nicholas A.J. Botwood Sells 31,235 Shares

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CMO Nicholas A.J. Botwood sold 31,235 shares of the firm’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $18.14, for a total value of $566,602.90. Following the completion of the sale, the chief marketing officer directly owned 60,885 shares in the company, valued at approximately $1,104,453.90. This represents a 33.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Nicholas A.J. Botwood also recently made the following trade(s):

• On Thursday, June 11th, Nicholas A.J. Botwood sold 34,280 shares of Syndax Pharmaceuticals stock. The stock was sold at an average price of $18.00, for a total value of $617,040.00.

Syndax Pharmaceuticals Price Performance

Shares of SNDX stock traded up $0.34 on Friday, hitting $18.25. 1,048,610 shares of the company’s stock were exchanged, compared to its average volume of 1,515,450. The company has a 50 day moving average of $21.17 and a 200 day moving average of $21.24. The stock has a market cap of $1.62 billion, a P/E ratio of -6.54 and a beta of 0.38. The company has a debt-to-equity ratio of 8.26, a current ratio of 5.47 and a quick ratio of 5.06. Syndax Pharmaceuticals, Inc. has a 12 month low of $8.59 and a 12 month high of $25.59.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.11. The business had revenue of $64.86 million for the quarter, compared to analyst estimates of $69.76 million. Syndax Pharmaceuticals had a negative return on equity of 256.65% and a negative net margin of 111.88%.Syndax Pharmaceuticals’s revenue was up 224.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.98) earnings per share. On average, equities research analysts predict that Syndax Pharmaceuticals, Inc. will post -1.66 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on SNDX shares. Mizuho reduced their price objective on Syndax Pharmaceuticals from $45.00 to $43.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 31st. Stifel Nicolaus set a $45.00 price objective on Syndax Pharmaceuticals in a research note on Friday, February 27th. UBS Group reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a report on Friday. JPMorgan Chase & Co. raised their price objective on Syndax Pharmaceuticals from $33.00 to $45.00 and gave the company an “overweight” rating in a report on Monday, March 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $42.55.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC increased its position in Syndax Pharmaceuticals by 3.2% in the 1st quarter. Hsbc Holdings PLC now owns 23,461 shares of the company’s stock valued at $556,000 after acquiring an additional 730 shares during the period. Pallas Capital Advisors LLC increased its holdings in Syndax Pharmaceuticals by 8.7% in the fourth quarter. Pallas Capital Advisors LLC now owns 10,985 shares of the company’s stock valued at $231,000 after purchasing an additional 875 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Syndax Pharmaceuticals by 26.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company’s stock valued at $89,000 after purchasing an additional 893 shares during the period. Schroder Investment Management Group increased its holdings in Syndax Pharmaceuticals by 1.0% in the third quarter. Schroder Investment Management Group now owns 123,404 shares of the company’s stock valued at $1,920,000 after purchasing an additional 1,241 shares during the period. Finally, Verition Fund Management LLC increased its holdings in Syndax Pharmaceuticals by 7.5% in the fourth quarter. Verition Fund Management LLC now owns 18,460 shares of the company’s stock valued at $388,000 after purchasing an additional 1,281 shares during the period.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.